MediPharm Announces Complete Dismissal of Defamation Action Initiated by Apollo, Nobul and Regan McGee Under Ontario Anti-SLAPP Law

Core Points - MediPharm Labs Corp. has successfully dismissed a $50 million defamation claim against its CEO and Chairman by Apollo Technology Capital Corporation and Nobul Technologies Inc. [1][2][3] - The Ontario Superior Court found that the claims were baseless and that the plaintiffs failed to provide evidence of harm caused by the statements made in a letter related to a proxy contest [3] - The company has also reported unauthorized press releases related to Apollo that were disseminated without its consent [4] Company Overview - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, operating under Good Manufacturing Practices [5] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for cannabinoid extraction [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada and internationally [7]